Certara accelerates medicines using proprietary biosimulation software, technology, and services to
transform traditional drug discovery and development, speed regulatory approvals, and ensure regulatory compliance. Its clients include over 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.

As the leading technology and services provider in clinical trial transparency and disclosure, Certara provides technology-enabled advanced anonymization and redaction services for posting regulatory documents and clinical trial data in the public domain. These services include compliance assessment, consulting and project leadership, and remediation planning.

Certara has been at the forefront of the transparency movement since the inception of EMA Policy 43 in 2010, including the support of proactive report disclosure by large pharma before regulations were introduced. Certara was the first to provide an artificial intelligence (AI)-enabled redaction technology solution with built-in patient privacy algorithms to the marketplace.